Germany-based Labtec Pharma designs and develops innovative drug delivery systems such as transdermal, buccal and gingival delivery and fast dissolving dosage forms. It also researches and develops contract analytics and stability testing according to the ICH standards.

Dr Ingo Lehrke, managing director at Labtec Pharma spoke to Pharmalicensing about his time and experience with the partnering company since first profiling a few years ago. “Pharmalicensing has many useful features; the licensing opportunities are easy to use and are effective, and inclusion on the website gives a strong visibility to the pharma industry. The cost of joining is affordable too.”

“The site is clear and the company has good customer relationships. It’s nice to receive a regular call from the same member of the Pharmalicensing team every month; my personal business development representative knows my history and what has been successful for me.” Dr Lehrke was also pleased with the website’s facilities, stating, “The search engine produces excellent results and we get good responses from our email alerts. The monthly reports are also useful.”

Earlier this year Labtec Pharma placed a new press release and three licensing opportunities on the Pharmalicensing website. After the release of this company information, Labtec Pharma received three to four times more interest on its profile and a significant increase of clicks to its website.

Dr Lehrke says that profiling with Pharmalicensing has allowed Labtec Pharma to reach companies and contacts that it would not normally reach. The company has initiated some licensing agreements with companies contacted through Pharmalicensing. “In the future I hope that Labtec’s inclusion on Pharmalicensing should lead to more deals for the company,” commented Dr Lehrke. “I am currently recommending Pharmalicensing to corporate officers at Schwarz Pharma in Mannheim, Germany.”